Syncona Full Year Results 2026: New Investment Policy, £250m Return Plan, and Portfolio Progress

Syncona full year results 2026: flat NAV, sharper strategy, and a clear £250 million shareholder return target

Syncona has had one of those years where the headline numbers look fairly calm, but the strategic change is doing the real heavy lifting. Net assets ended the year at £1,037.7 million, or 170.6p per share, versus £1,053.1 million and 170.9p a year earlier. That means the NAV per share – net asset value, effectively the value of the portfolio minus liabilities – slipped just 0.2%.

On the face of it, that is pretty flat. But this was not a nothing year. Syncona has reset its game plan, won shareholder backing for that reset, and is now focused on returning at least £250 million to shareholders by realising value from its maturing biotech portfolio.

Key number	FY2026	FY2025
Net assets	£1,037.7 million	£1,053.1 million
NAV per share	170.6p	170.9p
NAV per share return	(0.2)%	(9.5)%
Life science portfolio value	£839.4 million	£765.4 million
Capital pool	£198.3 million	£287.7 million
Capital deployed in the year	£80.9 million	£135.2 million

What Syncona’s new £250 million return plan means for shareholders

This is the bit that matters most. Shareholders approved a new Investment Policy with 90% support, and Syncona is now prioritising the return of a minimum of £250 million to investors in a timely manner.

In plain English, the company is shifting from “build a bigger empire” to “turn portfolio progress into cash and send some of it back”. That is a major change. Syncona has also dropped its old 2032 ambitions, including growing assets to £5 billion and creating three new companies per year.

I think that is a sensible pivot. Syncona has been trading at a material discount to NAV – the exact discount is not disclosed in this RNS – and investment trusts with wide discounts often need to prove value with hard cash, not just promising science. If Syncona can realise assets at decent prices and return proceeds through buybacks, a tender offer or a special dividend, that could help close the gap between its share price and portfolio value.

The important nuance is that management is not planning fire sales. The company explicitly says it wants to avoid “quick, value destructive exit options”. That is encouraging, because biotech assets can be worth a lot more once clinical data lands.

Beacon leads the gains, but Kesmalea and CRT Pioneer Fund drag on Syncona NAV

The financial performance was held together by Beacon Therapeutics. Beacon’s valuation rose by £37.5 million in the year, with Syncona’s stake written up by 31.9% after an oversubscribed $75.2 million Series C funding round led by Goldman Sachs Alternatives.

That matters because it shows outside investors are willing to back one of Syncona’s biggest assets at a higher value. In this market, third-party validation is gold dust.

Not everything went right. Kesmalea was written down by 54.2% to £9.2 million, reflecting investor interest at a lower valuation and weak conditions for early-stage private biotech. CRT Pioneer Fund also took a heavy hit, falling from £27.3 million to £10.2 million. Autolus slipped to £30.1 million from £34.6 million as its quoted share price remained volatile.

So the mixed picture is clear enough: late-stage and clinically advancing assets are doing the work, while earlier-stage holdings are still under pressure. That fits the new strategy almost perfectly.

Syncona portfolio progress: more late-stage biotech exposure is the whole point

Syncona now has 85.7% of its life science portfolio in nine clinical-stage and commercial companies. Of those, two are late-stage clinical and one already has a marketed product. That is a more mature mix than many retail investors might assume.

The company also says 83.7% of gross capital deployed in the year went into clinical or late-stage clinical assets. Again, that is exactly what you would want to see if the goal is near-term value realisation rather than blue-sky science.

• Spur Therapeutics started its Phase III programme in Gaucher disease
• Purespring Therapeutics initiated its Phase I/II programme in IgA nephropathy
• Resolution Therapeutics is progressing towards an interim Phase I/II data readout in H2 2026
• iOnctura is heading towards Phase II data in uveal melanoma in CY2026

For retail investors, “Phase III” and “pivotal” are worth watching. Those are late-stage clinical trials that can underpin regulatory filings if results are good. They are often the moments when biotech valuations move sharply, for better or worse.

Four key Syncona catalysts in 2026 could decide whether the return plan works

Management says the portfolio has eight key value inflection points through to the end of CY2028, with four due by the end of CY2026. These are the milestones that could lift NAV and create liquidity events such as partnerships, financings, IPOs or trade sales.

The standout near-term events are Beacon and iOnctura. Beacon is due to report data from its Phase II/III VISTA trial in XLRP in H2 2026. If positive, that could support a BLA – a Biologics License Application, essentially a request for approval in the US. iOnctura is due Phase IIb data in metastatic uveal melanoma this year as well.

This is where the investment case gets interesting. Syncona is basically saying: judge us on data, not just on marks in a spreadsheet. I think that is fair, but it also makes the story much more binary. If the readouts are strong, the new strategy could look smart very quickly. If they disappoint, the £250 million return plan becomes harder.

Syncona cash position, costs and capital discipline: solid, but not perfect

The capital pool fell to £198.3 million from £287.7 million, reflecting deployment into the portfolio. Even so, that is still a sizeable war chest, and Syncona says it is funded to deliver all eight key value inflection points.

That reduces financing risk, which is a big deal in biotech. At the year end, the capital pool included £46.1 million in cash, £81.9 million in credit funds, £77.7 million in multi-asset funds and £1.6 million in private equity funds.

Costs deserve a mention too. General expenses rose to £25.4 million from £17.7 million, partly due to one-off costs linked to the Investment Policy change. The ongoing charges ratio increased to 1.84% from 1.62%. That is not disastrous, but it is not trivial either. Syncona needs those future value realisations to justify the running costs.

Board changes and incentive reset show Syncona is serious about delivery

There is a fair bit of boardroom reshuffling here. Chair Melanie Gee will not stand for re-election at the 2026 AGM and intends to retire by the 2027 AGM. Norman Crighton joins the board from 1 July 2026, while Gian-Piero Reverberi will step down by the end of the year.

More important than the people changes is the incentive change. Shareholders approved new long-term incentives for the SIML team that are aligned with the new policy and linked to realisations. That is the right move. If the goal is to turn paper value into cash returns, management should be paid for doing exactly that.

My view on Syncona’s 2026 results: more investable now, but clinical risk still rules

I’d call this update strategically positive, financially steady, and operationally encouraging. The portfolio is maturing, Beacon has provided real validation, and Syncona now has a much clearer plan for unlocking value for shareholders.

The negatives are obvious enough: NAV was basically flat, the capital pool is smaller, some early-stage assets were marked down, and biotech remains a risky sector where one trial can change the picture overnight. None of that should be glossed over.

But overall, Syncona looks more investable today than it did a year ago because the company has stopped trying to be everything at once. The market will now focus on two things – whether clinical data lands well, and whether management can actually convert progress into the promised £250 million-plus return to shareholders. If it can, this could be the start of a re-rating. If not, the discount debate will rumble on.